<DOC>
	<DOCNO>NCT01774071</DOCNO>
	<brief_summary>The purpose study see new diagnostic research agent name 89Zr-DFO-MSTP2109A show prostate cancer tumor PET scan ; well see long 89Zr-DFO-MSTP2109A last blood give small amount . DFO-MSTP2109A antibody work STEAP1 - find surface prostate cancer cell . Attached DFO-MSTP2109A radioactive material call 89ZR , allow image PET scanner . The result study may help researcher know whether 89Zr-DFO-MSTP2109A use diagnostic agent find prostate cancer STEAP1 surface PET scanner . The reason identify STEAP1 prostate cancer cell new therapy develop target STEAP1 prostate cancer cell .</brief_summary>
	<brief_title>Study 89Zr-DFO-MSTP2109A Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>To include study , patient eligible enrollment protocol 11016 ( therapy DSTP3086S ADC ) meet follow criterion : Patients meet criteria enrollment research protocol 11016 receive DSTP3086S ADC ( therapeutic ADC base MSTP2109A ) prefer patient study . Patients receive DSTP3086S inject DSTP2086S image 89ZrDFOMSTP2109A finish , approximately 1 week . Adult male &gt; 21years age Visible lesion either CT , bone scan MRI consistent metastatic disease Metastatic progressive disease Imaging modality : Bone scan : new osseous lesion and/or MRI CT : An increase measurable soft tissue disease appearance new site disease . Or PSA change range value 26 % Patients histologically confirm prostate cancer MSKCC STEAP1 antigen positive tissue know prior IHC test STEAP1 status know archival sample send Genentech IHC . Samples need positive , feasible metastatic lesion test preferentially rather primary . Performance status 60 high ( Karnofsky scale ) ( Appendix A ) Ability understand willingness sign write informed consent document PSA level take within 2 week antibody administration . Patients meet follow exclusion criterion eligible study entry : Previous anaphylactic reaction human , humanize chimeric antibody Hematologic Platelets &lt; 75K/mcL ANC &lt; 1.0 K/mcL Hepatic laboratory value AST/ALT &gt; 2.5 x ULN Renal laboratory value Bilirubin &gt; 1.5 x ULN ( institutional upper limit normal ) eGFR &lt; 30mL/min/1.73m2 Patients history hypersensitivity reaction component 89ZrDFOMSTP2109A , include DFO</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>89Zr-DFO-MSTP2109A</keyword>
	<keyword>tracer</keyword>
	<keyword>pet scan</keyword>
	<keyword>12-178</keyword>
</DOC>